Portal de Periódicos da CAPES

Pharmacological and initial therapeutic observations on 6-Diazo-5-Oxo-L-Norleucine (Don) in human neoplastic disease

1957; Wiley; Volume: 10; Issue: 6 Linguagem: Inglês

10.1002/1097-0142(195711/12)10

1097-0142

Gordon B. Magill, W. P. Laird Myers, H. Christine Reilly, Richard C. Putnam, Judy Magill, Marguerite P. Sykes, George C. Escher, David A. Karnofsky, Joseph H. Burchenal,

DNA Repair Mechanisms

CancerVolume 10, Issue 6 p. 1138-1150 ArticleFree Access Pharmacological and initial therapeutic observations on 6-Diazo-5-Oxo-L-Norleucine (Don) in human neoplastic disease G. B. Magill M.D., G. B. Magill M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorW. P. L. Myers M.D., W. P. L. Myers M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorH. C. Reilly PH.D., H. C. Reilly PH.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorR. C. Putnam M.D., R. C. Putnam M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorJ. W. Magill M.D., J. W. Magill M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorM. P. Sykes M.D., M. P. Sykes M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorG. C. Escher M.D., G. C. Escher M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorD. A. Karnofsky M.D., D. A. Karnofsky M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorJ. H. Burchenal M.D., J. H. Burchenal M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this author G. B. Magill M.D., G. B. Magill M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorW. P. L. Myers M.D., W. P. L. Myers M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorH. C. Reilly PH.D., H. C. Reilly PH.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorR. C. Putnam M.D., R. C. Putnam M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorJ. W. Magill M.D., J. W. Magill M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorM. P. Sykes M.D., M. P. Sykes M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorG. C. Escher M.D., G. C. Escher M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorD. A. Karnofsky M.D., D. A. Karnofsky M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this authorJ. H. Burchenal M.D., J. H. Burchenal M.D. Divisions of Clinical and Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research; and the Chemotherapy Service, Department of Medicine, Memorial and James Ewing Hospitals, New York, New YorkSearch for more papers by this author First published: November/December 1957 https://doi.org/10.1002/1097-0142(195711/12)10:6 3.0.CO;2-KCitations: 60AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Bodansky, O.: Serum phosphohexose isomerase in cancer; I, method of determination and establishment of range of normal values. Cancer 7: 1191– 1199, 1954. 2 Burchenal, J. H., and Dagg, M. K.: Effects of 6-diazo-5-oxo-L-norleucine and 2-ethylamino-thiadiazole on strains of transplanted mouse leukemia. Proc. Am. A. Cancer Research 2: 97– 98, 1956. 3 Clarke, D. A.; Reilly, H. C., and Stock, C. C.: Comparative study of 6-diazo-5-oxo-L-norleucine and O-diazoacetyl-L-serine on Sarcoma 180. Proc. Am. A. Cancer Research 2. 100, 1956. 4 Dagg, C. P., and Karnofsky, D. A.: Protection against teratogenic action of azaserine and DON. Federation Proc. 15: 238, 1956. 5 Dagg, C. P.; Karnofsky, D. A.; Lacon, C., and Roddy, J.: Comparative effects of 6-diazo-5-oxo-L-norleucine and O-diazoacetyl-L-serine on the chick embryo. Proc. Am. A. Cancer Research 2: 101, 1956. 6 Ellison, R. R.; Karnofsky, D. A.; Sternberg, S. S.; Murphy, M. L., and Burchenal, J. H.: Clinical trials of O-diazoacetyl-L-serine (azaserine) in neoplastic disease. Cancer 7: 801– 814, 1954. 7 Magill, G. B.; Tan, C. T. C.; Reilly, H. C.; Putnam, R. C.; Addio, A. C., and Burchenal, J. H.: Preliminary clinical studies with 6-diazo-5-L-norleucine (DON) in neoplastic disease. Proc. Am. A. Cancer Research 2: 130, 1956. 8 Magill, G. B.: Unpublished observations. 9 Maxwell, R. E., and Nickel, V. S.: 6-Diazo-5-oxo-L-norleucine, new tumor-inhibitory substance; micro-biological studies of mode of action. In Abstracts of Papers, 129th Meeting. New York. Am. Chem. Soc. 1956; p. 15M. 10 Myers, W. P. L., and Magill, G. B.: Alterations in calcium metabolism in cancer patients treated with 6-diazo-5-oxo-L-norleucine. Proc. Sc. Exper. Biol. & Med. 93: 314– 318, 1956. 11 Reilly, H. C.: Inactivation of azaserine by liver enzyme. Federation Proc. 13: 279, 1954. 12 Reilly, H. C.: Unpublished data. 13 Spies, T.: Personal communication to Burchenal, J. H., 1956. 14 Sternberg, S. S.; Philips, F. S., and Clarke, D. A.: Pancreatitis and other pathological changes in rats given azaserine (AZS). Federation Proc. 13: 444, 1954. 15 Sternberg, S. S.; Scholler, J., and Philips, F. S.: Comparative study of pathological effects of 6-diazo-5-oxo-L-norleucine (DON) and its analog, azaserine. Proc. Am. A. Cancer Research 2: 150, 1956. 16 Sugiura, K., and Schmid, M. S.: Effects of antibiotics on growth of variety of mouse and rat tumors. Proc. Am. A. Cancer Research 2: 151– 152, 1956. 17 Sugiura, K. and Stock, C. C.: Effect of O-diazoacetyl-L-serine (azaserine) on growth of various mouse and rat tumors. Proc. Soc. Exper. Biol. & Med. 88: 127– 129, 1955. 18 Wróblewski, F., and LaDue, J. S.: Lactic dehydrogenase activity in blood. Proc. Soc. Exper. Biol. & Med. 90: 210– 213, 1955. Citing Literature Volume10, Issue6November/December 1957Pages 1138-1150 ReferencesRelatedInformation